Day One Biopharmaceuticals (NASDAQ:DAWN) Lowered to Hold Rating by Needham & Company LLC

Needham & Company LLC lowered shares of Day One Biopharmaceuticals (NASDAQ:DAWN) from a buy rating to a hold rating in a research report sent to investors on Friday, MarketBeat reports.

A number of other brokerages also recently commented on DAWN. HC Wainwright lowered their price objective on shares of Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. JPMorgan Chase & Co. lifted their price objective on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Wedbush raised their price target on Day One Biopharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Zacks Research lowered Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $25.56.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ:DAWN traded up $8.42 during midday trading on Friday, reaching $21.20. The company had a trading volume of 78,369,097 shares, compared to its average volume of 2,410,501. Day One Biopharmaceuticals has a 1-year low of $5.64 and a 1-year high of $21.23. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of -20.58 and a beta of -1.25. The company has a fifty day simple moving average of $11.10 and a two-hundred day simple moving average of $9.05.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The firm had revenue of $53.72 million during the quarter, compared to analysts’ expectations of $49.81 million. Analysts expect that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

Insider Activity at Day One Biopharmaceuticals

In other news, insider Adam Dubow sold 6,395 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $74,182.00. Following the completion of the sale, the insider owned 72,694 shares in the company, valued at approximately $843,250.40. This represents a 8.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Charles N. York II sold 6,065 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $70,354.00. Following the completion of the transaction, the chief financial officer directly owned 312,025 shares in the company, valued at $3,619,490. The trade was a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 36,461 shares of company stock worth $422,948 in the last 90 days. Insiders own 6.20% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

Several large investors have recently modified their holdings of DAWN. Mirae Asset Global Investments Co. Ltd. raised its holdings in Day One Biopharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after acquiring an additional 1,029 shares during the period. Federated Hermes Inc. bought a new stake in Day One Biopharmaceuticals during the third quarter valued at about $39,000. Quarry LP acquired a new stake in shares of Day One Biopharmaceuticals in the third quarter valued at about $49,000. Ameritas Investment Partners Inc. increased its stake in shares of Day One Biopharmaceuticals by 44.5% in the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after purchasing an additional 2,264 shares during the period. Finally, CWM LLC increased its stake in shares of Day One Biopharmaceuticals by 32.4% in the fourth quarter. CWM LLC now owns 8,373 shares of the company’s stock worth $78,000 after purchasing an additional 2,051 shares during the period. 87.95% of the stock is owned by institutional investors.

More Day One Biopharmaceuticals News

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Acquisition announced — Servier agreed to buy Day One for $21.50 per share in cash (~$2.5 billion), a deal that crystallizes a takeover premium and explains the sharp rally; the transaction is subject to customary closing conditions and is expected to close in Q2 2026. Article Title
• Positive Sentiment: Analyst target raised — JonesTrading reiterated a “hold” but increased its price target to $21.50 (from $20.00), putting its target in line with the buyout price and reinforcing the deal valuation. Article Title
• Positive Sentiment: Options and volume spike — Unusual call-option activity and extremely high trading volume point to takeover-driven speculative buying and arbitrage interest ahead of the deal close (increased open interest and buy-side activity tend to amplify intraday moves).
• Neutral Sentiment: Trading halt — Shares were temporarily halted earlier for “News pending,” a standard market pause when material corporate announcements are imminent; this is procedural and common around M&A.
• Neutral Sentiment: Ratings reaffirmed — Needham and JonesTrading reaffirmed their “hold” ratings (Needham also maintained its view) even as price targets moved; these keep analyst sentiment mixed despite the takeover. Article Title
• Negative Sentiment: Multiple shareholder investigations and potential litigation — Several law firms (e.g., Brodsky & Smith, Ademi LLP, Halper Sadeh, Monteverde & Associates) announced probes into whether the Board obtained a fair price and followed a proper process; lawsuits or injunctions could delay closing, increase deal costs, or put pressure on the eventual net proceeds to shareholders. Article Title Article Title

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.